FDA’s Temple: Better Meta-Analyses Needed Ahead Of Agency Guidance
This article was originally published in The Pink Sheet Daily
Senior FDA officials call for prospective planning and transparency in meta-analysis conduct; they also discuss potential for a “refuse-to-file” type of standard for meta-analyses that don’t meet certain format and content standards worthy of agency consideration.
You may also be interested in...
Three years overdue, agency draft guidance seeks to inject a threshold level of rigor into meta-analyses of randomized, controlled trials to evaluate drug safety and proposes a three-tiered hierarchy of evidence against which FDA will evaluate such studies for regulatory decision-making purposes.
Agency plans to issue 102 new and revised draft guidances this year, including those on use of multiple endpoints in clinical trials, 180-day exclusivity, and ANDA refuse-to-receive standards.
Comforted by the re-adjudicated RECORD results, agency directs rosiglitazone sponsors to provide training “based on the current state of knowledge” about the diabetes drug’s cardiovascular risk but eliminates the requirement that links drug access to provider, pharmacy and patient enrollment in the REMS.